Best Ketamine Therapy for Veterans with PTSD: IV, At-Home, and Spravato Compared

Side-by-Side Comparison Table

Cross-study note: the response rates in the table above come from different studies using different instruments (Mindbloom's self-reported PCL-5 versus the clinician-rated CAPS-5 used in the IV trials) and are not direct head-to-head comparisons.

How PTSD Affects Veterans

According to the VA's National Center for PTSD, about 7 in 100 veterans will experience PTSD in their lifetime, a rate that climbs to nearly 29% among those who served in Iraq or Afghanistan and is higher still among women veterans.8 Post-traumatic stress disorder involves a specific set of neurological and psychological responses to severe trauma, and veterans often develop it following combat trauma, military sexual trauma, or repeated deployment exposure.

Core PTSD symptom clusters include:

• Hypervigilance: A constant state of high alert and scanning for threats.
• Flashbacks: Intrusive memories or feeling as though the trauma is happening again.
• Avoidance: Staying away from places, people, or thoughts that trigger memories.
• Emotional numbness: Difficulty feeling positive emotions or connecting with loved ones.
• Sleep disturbance: Severe insomnia or frequent nightmares.
• Irritability: Quick temper, angry outbursts, or aggressive behavior.
• Moral injury: Deep psychological wounds from actions that violate personal moral codes.

Why First-Line PTSD Treatment Falls Short for Many Veterans

First-line treatment under the VA/DoD Clinical Practice Guideline typically includes trauma-focused psychotherapies such as prolonged exposure and cognitive processing therapy, alongside SSRIs like sertraline and paroxetine.9 A significant share of veterans do not achieve remission with these approaches, earning a "treatment-resistant" designation in the VA system, and many report frustration with long waitlists and medication cycling.4,5 Veterans with service-connected PTSD, those managing military sexual trauma, and those in VA Community Care all navigate this same first-line pathway before alternatives are considered.

For veterans who reach that point, realistic goals for ketamine therapy include:

• Meaningful reduction in PCL-5 and CAPS-5 assessment scores.
• Improved daily functioning and restored capacity for relationships and work.
• Reduced reliance on medications that cause side effects, such as SSRIs and benzodiazepines.

How Ketamine Therapy Helps PTSD

Ketamine therapy temporarily modulates neural communication to help the brain build new, healthier pathways. The medicine adjusts glutamate signaling and temporarily changes activity at NMDA receptors in the brain. In turn, this cascade increases neuroplasticity: the brain's ability to form new neural connections and weaken entrenched trauma-driven pathways.

Unlike traditional SSRIs, which modulate serotonin and often take weeks to show effects, ketamine works through a fundamentally different mechanism. Ketamine's neuroplasticity window opens rapidly, and many people report noticeable symptom relief within hours or days of their first session.

A robust body of clinical research has studied ketamine for PTSD, much of it conducted specifically in veterans and active-duty service members, though the results are mixed rather than settled. A repeated-infusion trial published in the American Journal of Psychiatry reported rapid symptom reduction over a six-session course, with a large effect size.¹ The veteran-specific evidence is detailed in the research section below.

More durable benefits typically develop over a series of sessions. Because ketamine opens a neuroplasticity window, integration practices between sessions help sustain progress over time.

What the Research Shows in Veterans and Active-Duty Populations

Most of the published clinical trials of ketamine for PTSD were run in veterans or active-duty service members, which makes this one of the few conditions where the trial population closely matches the people asking the question. Results across those in-clinic IV trials are inconsistent, and honest reporting matters here.

• Albott 2018: an open-label study of 15 veterans with comorbid PTSD and treatment-resistant depression used six IV infusions; 80% achieved PTSD remission.10
• Abdallah 2022: the largest and most rigorous trial to date, 158 veterans and active-duty service members, tested two IV doses against placebo and found no significant difference from placebo at either dose.3
• Rauch 2019: a trial of 207 combat veterans compared prolonged exposure therapy, sertraline, and the combination; clinically meaningful improvement topped out at 52% to 62%, with no single approach outperforming the others.5

Two things follow. First, the in-clinic IV trial base does not establish ketamine as a settled PTSD treatment, and the 2023 VA/DoD Clinical Practice Guideline reflects that by not recommending it as a standalone therapy.⁹ Second, every one of those trials delivered ketamine in a clinic, the setting PTSD symptoms make hardest to sustain. Mindbloom's real-world data comes from a different model: at-home subcutaneous ketamine over a six-session course with structured integration. In that peer-reviewed study, response and remission landed at or above the range reported in the veteran IV trials, measured on the self-reported PCL-5 rather than the clinician-rated CAPS-5 used in those trials.2 The comparison is directional, not head-to-head, because no trial has compared at-home subcutaneous ketamine to in-clinic care.

How At-Home Ketamine Works for PTSD

At-home ketamine therapy is an administration method, not a single company or protocol. It refers to sublingual tablets or subcutaneous injections prescribed by a licensed provider after a comprehensive medical evaluation, then self-administered at home under telehealth medical oversight. Several companies offer at-home ketamine programs, each with its own protocol, dosing approach, and level of clinical support.

One at-home provider, Mindbloom, recently published a peer-reviewed study of its subcutaneous outcomes in the Journal of Medical Internet Research, in which 84.6% of participants reported clinically meaningful improvement in PTSD symptoms after six sessions, with a 76.7% response rate and a 56.7% remission rate.²

In addition to those published outcomes, Mindbloom offers a specific PTSD program: a tailored course of preparation, integration, and session audio content, developed in collaboration with trauma and PTSD expert Shari Botwin and designed to apply the medicine specifically to trauma. Other at-home providers also offer ketamine therapy for PTSD, each with its own protocol and care model.

Mindbloom's at-home protocol involves strict provider supervision and defined safety measures, including telehealth medical oversight and a required peer treatment monitor present during each session; safety protocols vary by provider. Healing in a familiar, safe setting can support deeper therapeutic experiences, which is particularly valuable for veterans dealing with hypervigilance or institutional distrust.

How IV Ketamine Works for PTSD

Intravenous ketamine therapy delivers the medicine directly into the bloodstream in a medical setting. Care staff administer the infusion at a specialty clinic or hospital, with sessions typically lasting 40 to 60 minutes plus additional observation time. A standard induction course commonly involves six infusions over two to three weeks, followed by maintenance infusions as needed.

Each visit requires the veteran to travel to a clinic and receive an IV line. Staff track vital signs like blood pressure, heart rate, and oxygen saturation in real time. Intravenous delivery provides high bioavailability and precise dose control.

Many IV clinics focus primarily on the infusion itself without offering preparation, post-session coaching, or therapeutic programming. The experience can vary significantly between clinics because there is no single standardized IV ketamine protocol for PTSD.

Published evidence for IV ketamine in PTSD is more limited than for depression, and the trial results are inconsistent. Those trials, most of them conducted in veterans and active-duty service members, are detailed in the research section above. Inconsistent results do not mean IV ketamine is ineffective for PTSD, but rather that the evidence base is still evolving.

For veterans who prefer in-person medical supervision and have access to a quality infusion clinic, intravenous treatment is a legitimate option. The primary barriers are high out-of-pocket costs, geographic access limitations, and the logistical burden of repeated in-person visits.

How Spravato (Esketamine) Treatment Works for PTSD

Spravato is an FDA-approved nasal spray manufactured by Janssen, utilizing a ketamine derivative called esketamine. It is the only FDA-approved ketamine-derived treatment, but its approved indications are treatment-resistant depression and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, not PTSD. Using Spravato for PTSD falls outside its approved indications.

Spravato must be administered in a REMS-certified healthcare facility, meaning the veteran cannot take it home. Each session requires a minimum two-hour monitored observation window, and prescribers must be enrolled in the Spravato REMS program.

Because PTSD is not an approved indication, insurance coverage typically requires a comorbid depression diagnosis, prior authorization, and documentation that the veteran has tried and failed multiple standard treatments. These requirements create significant friction, and REMS-certified providers remain limited outside major metropolitan areas.

For veterans whose primary diagnosis is PTSD without comorbid depression, Spravato may not be the most direct path to treatment.

Is Daily Low-Dose Ketamine Effective for PTSD?

Daily low-dose ketamine involves taking sub-perceptual oral doses every day, low enough to avoid dissociative or psychedelic effects. Some at-home providers offer it as an alternative to structured, therapeutic-dose sessions. However, no peer-reviewed randomized controlled trials or published outcomes data exist for daily low-dose ketamine in PTSD populations, so its safety and effectiveness cannot be substantiated for PTSD. Ketamine's broader evidence base for PTSD does not extend to daily low-dose use; the two are different interventions with different dosing and pharmacological profiles.

Cost and Access for Veterans With VA Community Care and Insurance

The cost and access landscape for veterans seeking ketamine therapy depends heavily on the chosen modality. Ketamine for PTSD is off-label regardless of delivery method, which affects insurance coverage, VA authorization pathways, and out-of-pocket costs, covered in detail below. Private insurance rarely covers compounded ketamine, though HSA and FSA funds can typically be used to pay for programs such as Mindbloom's.

Does the VA cover ketamine therapy for PTSD?

Not directly, and not routinely. The VA does not cover ketamine as a standard PTSD benefit, because ketamine is not FDA-approved for PTSD and the 2023 VA/DoD Clinical Practice Guideline does not recommend it for that indication.9 Two indirect pathways exist. First, some veterans access ketamine through the VA Community Care Network by referral, described below, though approval is not guaranteed. Second, because PTSD is frequently comorbid with treatment-resistant depression, and ketamine and Spravato are supported for treatment-resistant depression, some veterans qualify through a depression diagnosis. Spravato specifically may be available at some VA facilities for treatment-resistant depression.

Does TRICARE cover ketamine therapy?

TRICARE, which covers active-duty service members, retirees, and their families, generally does not cover compounded or off-label ketamine for PTSD. Coverage for Spravato may be available for treatment-resistant depression with prior authorization. As with the VA, PTSD-specific ketamine use typically falls outside covered benefits, so most veterans and service members using at-home ketamine pay out of pocket, often with HSA or FSA funds."

How the VA Community Care Referral Process Works for Ketamine Therapy

The Community Care Network referral pathway involves several specific steps. Veterans Affairs ketamine guidelines are not standardized across all facilities, meaning access varies by location and individual provider willingness to refer.

A veteran typically must:

1. Be enrolled in VA healthcare.
2. Have a PTSD diagnosis documented in their VA record.
3. Have tried and failed multiple standard treatments, such as SSRIs and psychotherapy, as documented by their VA provider.
4. Receive a referral from their VA provider for community care.
5. Obtain prior authorization for off-label ketamine from the VA.

Referrals can take weeks to months, and approval is not guaranteed.

Why Rural Veterans Face Extra Barriers to IV and Spravato Treatment

A large share of the United States veteran population lives outside major metropolitan areas. Intravenous infusion clinics are concentrated in cities, and REMS-certified Spravato providers are even more limited in number and geography.

Both modalities require on-site visits with monitored observation windows, ranging from 30 minutes for IV to a minimum of two hours for Spravato. For a rural veteran, each session may require hours of travel each way, time off work, and arranging transportation since driving immediately after is not permitted.

Multiplying the travel time across six or more sessions in an induction course turns the logistical burden into a barrier to completing treatment.

At-home telehealth-based ketamine therapy, such as Mindbloom's program, is structurally the only option that does not require travel or repeated days away from home.

Ketamine Therapy Costs for At-Home, IV, and Spravato

Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, a licensed provider conducts a comprehensive medical evaluation to confirm your eligibility and personalize your care plan.

Cost comparison by modality:

• At-home: Mindbloom's at-home ketamine therapy is approximately 60% more affordable per session than IV clinics. For example, Mindbloom Pricing starts at $165 per session for a new client 18-session program, billed as $330 per month for nine months, or $215 per session for a 6-session program billed as $430 for three months. Returning Mindbloom clients pay as little as $129 per session for an 18-session program.
• IV ketamine clinics: Typically cost $400 to $800 or more per infusion. A six-session induction course can cost $2,400 to $4,800 and is rarely covered by insurance.
• Spravato: May be partially covered by insurance for depression with prior authorization and a refractory depression diagnosis. Copays vary, but the total cost includes the non-financial burden of REMS requirements and travel.

Free ketamine treatment for veterans is not currently a standard VA benefit. Some VA facilities or research programs may offer ketamine at no cost through medical trials, but these are limited and not widely available.

Which Option May Be the Best Fit for Veterans With PTSD

For veterans, choosing the right treatment path depends on individual treatment goals, symptom severity, and access barriers. The following points can help guide your decision.

At-home ketamine therapy through Mindbloom may be a fit if you:

• Want an evidence-based PTSD program with published outcomes in peer-reviewed journals.
• Live far from an IV infusion clinic or Spravato-certified provider.
• Prefer to heal in your own home rather than a medical setting.
• Are looking for a more affordable option than IV infusions.
• Want the option of subcutaneous administration.

IV ketamine may be a fit if you:

• Prefer in-person medical supervision during every session.
• Have access to a quality infusion clinic near you.
• Want the highest bioavailability per session and are comfortable with IV administration.
• Are comfortable with the cost and logistics of repeated clinic visits.

Spravato may be a fit if you:

• Have a comorbid treatment-resistant depression diagnosis and can obtain prior authorization.
• Have insurance that covers Spravato and access to a REMS-certified provider nearby.
• Prefer an FDA-approved product for your comorbid condition.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.